Rubicon's Q4 margin rebounds as revenue grows +8.07% sequentially
Expenses rose +7.57%, slower than revenue, but a 2.55-percentage-point rise in the tax rate limited net-profit growth to +5.47%.
Filed 29 May 2026, 17:21 IST · after market close · Rubicon Research Ltd (RUBICON)
Key takeaways
- Consolidated revenue grew +8.07% sequentially as expenses rose +7.57%, lifting operating margin by 0.36 percentage points.
- Net profit rose +5.47% sequentially as the tax rate increased 2.55 percentage points, while other income contributed 2.64% of pre-tax profit.
- The stock gained +16.46% on the reaction day, while Q4 operating margin was 0.28 percentage points below the 23.38% Healthcare peer median.
Price around the results
Revenue momentum lifted consolidated operating profit
Rubicon Research delivered sequential growth in consolidated revenue, with sales rising +8.07% from Q3FY26. Expenses increased more slowly at +7.57%, allowing operating profit to grow +9.78% and operating margin to improve by 0.36 percentage points.
Higher tax and interest costs diluted the profit conversion
The slower expense growth supported the margin recovery, but interest costs rose +6.04% sequentially. The tax rate increased 2.55 percentage points to 22.19%, so net profit grew +5.47%, below the +8.94% growth in pre-tax profit. Other income was only 2.64% of pre-tax profit, leaving reported profit largely tied to operations.
Margin recovered after the Q3 dip but remains just below peers
Operating margin moved from 22.89% in Q2FY26 to 22.74% in Q3FY26 before recovering to 23.10% in Q4FY26. It was 0.28 percentage points below the 23.38% median for the 48 Healthcare peers that had reported the quarter.
Management linked capacity constraints to outsourced manufacturing
Management said strong revenue traction and limited own-manufacturing capacity had increased reliance on outsourced manufacturing, while gross margin slipped to 66.3% from 66.5% sequentially. The company said it was evaluating measures that could reduce this reliance over two to three quarters and that production from Pithampur was expected to ramp up in Q1 CY27. Management also said operating EBITDA margin was expected to remain in the 22-23% range, and reported 12 product approvals in FY26 with 24 products under USFDA review as of March 31.
The stock extended its post-results move
The stock rose +16.46% on the reaction day after opening with a +3.85% gap.
Q4FY26 at a glance
Consolidated figures as filed with NSE — cross-checked against an independent source.
| Line item | Q4FY26 | Q3FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹514 cr | ₹476 cr | +8.07% |
| Other income | ₹3 cr | ₹4 cr | -31.13% |
| Expenses | ₹395 cr | ₹367 cr | +7.57% |
| Operating profit | ₹119 cr | ₹108 cr | +9.78% |
| Operating margin (%) | 23.10% | 22.74% | — |
| Interest | ₹10 cr | ₹10 cr | +6.04% |
| Depreciation | ₹12 cr | ₹12 cr | +6.23% |
| Profit before tax | ₹99 cr | ₹91 cr | +8.94% |
| Tax | ₹22 cr | ₹18 cr | +23.10% |
| Net profit | ₹77 cr | ₹73 cr | +5.47% |
| EPS (₹) | ₹4.66 | ₹4.46 | +4.48% |
Operating margin of 23.10% compares with a Healthcare sector median of 23.38% across 48 peers that have reported Q4FY26.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | +16.46% | +17.16% |
| Next session | +29.53% | — |
| 5 sessions | +17.48% | +19.29% |
| 15 sessions | +36.89% | — |
| 30 sessions | +48.30% | — |
Volume on the results session was 23.41× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- The company received 12 product approvals in FY26 and had 24 products under USFDA review as of March 31.
- The company commercialized 92% of approved products.
Guidance & outlook
- The company expects strong revenue visibility in the coming quarters.
- Operating EBITDA margin is expected to remain in the 22-23% range despite higher outsourced manufacturing.
- The company expects revenue traction to continue stronger than previously anticipated.
- The company remains on track for more than INR 5,000 million of R&D spending over nine quarters.
- The company expects similar R&D productivity to provide visibility for FY29/30 and beyond.
Expansion
- The company is evaluating measures that could reduce reliance on outsourced manufacturing within two to three quarters.
- Production from the Pithampur site is expected to ramp up in Q1 CY27.
New initiatives
- Validus Pharmaceuticals provides a platform for branded CNS launches in the US.
Competition
- Metoprolol Tartrate held a 37.3% market share and ranked first in FY25.
- Baclofen held a 35.3% market share and ranked first in FY25.
Problems & risks
- Own manufacturing capacity constraints increased reliance on outsourced manufacturing.
- Gross margin declined slightly sequentially to 66.3% from 66.5%.
What to watch
- Whether operating EBITDA margin remains within management's 22-23% range.
- Whether the Pithampur production ramp-up is reported in Q1 CY27 and outsourced-manufacturing reliance changes over two to three quarters.
- Whether the 92% commercialisation rate for approved products is maintained.